Loading
FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Trastuzumab.
In plain words · FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
Binds to the Fc region of immunoglobulins gamma. Low affinity receptor.
No product in this corpus aims at FCGR2A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FCGR2A: RNA tissue enhanced (lymphoid tissue 113 nTPM, placenta 127 nTPM); blood lineage lineage enriched (granulocytes 2,531 nTPM); high antibody staining in 2 normal tissues. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas FCGR2A tissue; Open Targets ENSG00000143226 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Stuart S.G. et al, J. Exp. Med, 1987, "Isolation and expression of cDNA clones encoding a human receptor for IgG (Fc gamma RII)". Source.
Sources: HGNC HGNC:3616 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P12318 (protein name, function text, keywords and locations (REST API)); CIViC gene FCGR2A (2 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, HER2 Positive Breast Cancer (GraphQL API, CC0))
Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonised antigens. Location: Cell membrane (UniProt). Locus 1q23.3 (HGNC).
RNA: tissue enhanced (lymphoid tissue 113 nTPM, placenta 127 nTPM), detected in all normal tissues. Blood: lineage enriched (granulocytes 2,531 nTPM).
Medium: Bone marrow, Spleen, Tonsil.
No cancer sample stained medium or high.
HPA FCGR2A tissue · HPA FCGR2A pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FCGR2A" OR ABSTRACT:"FCGR2A" OR TITLE:"Fc gamma receptor IIa" OR ABSTRACT:"Fc gamma receptor IIa" OR TITLE:"Low affinity immunoglobulin gamma Fc region receptor II-a" OR ABSTRACT:"Low affinity immunoglobulin gamma Fc region receptor II-a" OR TITLE:"CD32" OR ABSTRACT:"CD32" OR TITLE:"CD32A" OR ABSTRACT:"CD32A" OR TITLE:"IGFR2" OR ABSTRACT:"IGFR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FCGR2A, not a curated reading list.